Diabetes, Heart and Cardiovascular Diseases News Chronicle.  Diabetes, Cardiovascular and Heart Diseases
 Article 61
    Published on September 21, 2016


Partnership Between Lifescan And WellDoc

Lifescan inc and WellDoc companies partnered together to provide the best type 2 diabetes (T2D) management solutions with data analysis powered by BlueStar. As per the new agreement, companies are going to integrate first FDA cleared BlueStar diabetes management platform with LifeScan's blood glucose monitoring system.




       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. Usability Study Of WellDoc BlueStar Mobile App
2. Risks With Over Eating Of Omega-3 Fatty Acids
3. SGLT2 Inhibitor Drug Ertugliflozin
4. Chronic Kidney Disease, Heart Disease & Diabetes Prevention Drugs From Forxiga Drug Maker AstraZeneca
5. Risks To Left Ventricle And Heart Health

 

Lifescan Inc : Lifescan Inc is a Johnson & Johnson company having headquarters in Milpitas, California. The company manufactures and markets OneTouch Verio blood glucose monitoring system with smartphone support for homes, clinics, and hospitals.

WellDoc : WellDoc, Baltimore, Maryland is a healthcare company established in 2005. The company is in software services and products business helping patients and doctors in treating chronic diseases worldwide.

 

Storing Body Fat More efficiently

Researchers from the Anti-Doping Laboratory, Qatar (ADLQ) and the University of Bristol, UK found that some obese people are at LOWER RISK to health complications associated with extra weight. Researchers found that stem cells of lower-risk people (with extra weight) are storing fat more efficiently compared with other people of the same weight. Stem cells of lower risk people are not storing fat in important organs such as heart, liver, and kidney. Storing fat in important organs is a high-risk factor for diabetes, stroke or heart attacks. Researchers found that LOWER RISK individuals had fewer levels of "interleukin 6", a blood protein that controls body inflammation and infection responses. The levels of interleukin-6 are high with people having diseases associated with overweight. Now researchers are devising plans in using "interleukin-6" protein so that stem cells can store more fat in them instead of important organs during the pre-diabetic stage itself and prevent type 2 diabetes (T2D). Dr. Mohamed Elrayess (ADLQ) and Dr. Wael Kafienah (University of Bristol) are part of the research group.




       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. Benefits Of Beige Fat Cells
2. Complication With Belly Fat
3. Device To Release Drugs In Eye
4. Device To Predict Diabetes
5. Role Of Pioglitazone Diabetes Drug In Preventing Breast Cancer

 

Stem cells : Stem cells are found in the blood of an attached umbilical cord after birth. As organism ages, the stem cells take up specialized functionality in tissues or organs such as skin, blood, bone, muscle, liver etc. For example, red cells job is oxygen delivery. But stem cells are for an unspecialized purpose and can do any job or body function. Stem cells can

  • Divide themselves and become multiple cells
  • They have the power to form as a cell of any type of organism tissue

Important uses of stem cells are

  • Damaged cells can be replaced with stem cells to treat diseases such as blindness, paralysis etc.
  • Pharma drugs can be tested for quality and safety with stem cells instead of testing on humans
  • Scientists can study how diseases develop with stem cells

 

Trials Of GLP-1 (exenatide extended-release) And Farxiga (dapagliflozin)

AstraZeneca had conducted phase 3 trials and announced that their drugs were successful and reached the trial endpoint with a significant reduction in blood sugar levels in patients with type 2 diabetes (T2D). The drugs in phase 3 trials are


Phase 3 trial results were submitted at the 52nd Annual Meeting of the European Association (AMEA) in Munich, Germany. The phase 3 trial results were published in the Lancet Diabetes & Endocrinology. AstraZeneca is introducing the following drugs shortly.

  • Benralizumab drug to treat chronic obstructive pulmonary disease and asthma
  • Brodalumab drug to treat psoriasis
  • Tralokinumab drug to treat asthma
  • Anifrolumab drug to treat systemic lupus erythematosus
  • Roxadustat drug to treat anemia
  • AZD3293 drug to treat Alzheimer's disease



       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. Hormones GLP-1 And PYY
2. Study Of Exenatide Drug
3. Trials With Forxiga (Dapagliflozin), Victoza (Liraglutide) And Insulin Approach (Triple Therapy)
4. Device To Detect Deadly Ketones
5. About Revita DMR Device

 

GLP-1 : Gut endocrine cells located in the epithelium of the small intestine releases incretins metabolic hormones during meals. Incretins triggers an increase in production of insulin from beta cells (in pancreatic) and finally reduction in blood sugar levels after sugar absorption by body cells. There is two type of incretins hormones in humans and one of them is GLP-1 (glucagon-like peptide-1) hormone. GLP-1 receptor agonist mimic incretins hormones of the GLP-1 type to increase insulin production. The drug is an injectable type of drugs to treat type ii diabetes (T2D). These drugs are capable of reducing glucagon (a hormone that increases the concentration of glucose in the blood), reduces HbA1c levels, reduce weight. These drugs are low risk to hypoglycemia.

 

 

Site maps

Site map 1   Site map 2   Site map 3   Site map 4


The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.


Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.